Paediatric Nephrology
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
MYH9-Related Platelet Disorders
Reprinted with permission from Thieme Medical Publishers (Semin Thromb Hemost 2009;35:189-203) Homepage at www.thieme.com MYH9-Related Platelet Disorders Karina Althaus, M.D.,1 and Andreas Greinacher, M.D.1 ABSTRACT Myosin heavy chain 9 (MYH9)-related platelet disorders belong to the group of inherited thrombocytopenias. The MYH9 gene encodes the nonmuscle myosin heavy chain IIA (NMMHC-IIA), a cytoskeletal contractile protein. Several mutations in the MYH9 gene lead to premature release of platelets from the bone marrow, macro- thrombocytopenia, and cytoplasmic inclusion bodies within leukocytes. Four overlapping syndromes, known as May-Hegglin anomaly, Epstein syndrome, Fechtner syndrome, and Sebastian platelet syndrome, describe different clinical manifestations of MYH9 gene mutations. Macrothrombocytopenia is present in all affected individuals, whereas only some develop additional clinical manifestations such as renal failure, hearing loss, and presenile cataracts. The bleeding tendency is usually moderate, with menorrhagia and easy bruising being most frequent. The biggest risk for the individual is inappropriate treatment due to misdiagnosis of chronic autoimmune thrombocytopenia. To date, 31 mutations of the MYH9 gene leading to macrothrombocytopenia have been identified, of which the upstream mutations up to amino acid 1400 are more likely associated with syndromic manifestations than the downstream mutations. This review provides a short history of MYH9-related disorders, summarizes the clinical and laboratory character- istics, describes a diagnostic algorithm, presents recent results of animal models, and discusses aspects of therapeutic management. KEYWORDS: MYH9 gene, nonmuscle myosin IIA, May-Hegglin anomaly, Epstein syndrome, Fechtner syndrome, Sebastian platelet syndrome, macrothrombocytopenia The correct diagnosis of hereditary chronic as isolated platelet count reductions or as part of thrombocytopenias is important for planning appropri- more complex clinical syndromes. -
Alport Syndrome of the European Dialysis Population Suffers from AS [26], and Simi- Lar Figures Have Been Found in Other Series
DOCTOR OF MEDICAL SCIENCE Patients with AS constitute 2.3% (11/476) of the renal transplant population at the Mayo Clinic [24], and 1.3% of 1,000 consecutive kidney transplant patients from Sweden [25]. Approximately 0.56% Alport syndrome of the European dialysis population suffers from AS [26], and simi- lar figures have been found in other series. AS accounts for 18% of Molecular genetic aspects the patients undergoing dialysis or having received a kidney graft in 2003 in French Polynesia [27]. A common founder mutation was in Jens Michael Hertz this area. In Denmark, the percentage of patients with AS among all patients starting treatment for ESRD ranges from 0 to 1.21% (mean: 0.42%) in a twelve year period from 1990 to 2001 (Danish National This review has been accepted as a thesis together with nine previously pub- Registry. Report on Dialysis and Transplantation in Denmark 2001). lished papers by the University of Aarhus, February 5, 2009, and defended on This is probably an underestimate due to the difficulties of establish- May 15, 2009. ing the diagnosis. Department of Clinical Genetics, Aarhus University Hospital, and Faculty of Health Sciences, Aarhus University, Denmark. 1.3 CLINICAL FEATURES OF X-LINKED AS Correspondence: Klinisk Genetisk Afdeling, Århus Sygehus, Århus Univer- 1.3.1 Renal features sitetshospital, Nørrebrogade 44, 8000 Århus C, Denmark. AS in its classic form is a hereditary nephropathy associated with E-mail: [email protected] sensorineural hearing loss and ocular manifestations. The charac- Official opponents: Lisbeth Tranebjærg, Allan Meldgaard Lund, and Torben teristic renal features in AS are persistent microscopic hematuria ap- F. -
Case Report Two Cases of the MYH9 Disorder Fechtner Syndrome Diagnosed from Observation of Peripheral Blood Cells Before End-Stage Renal Failure
Hindawi Case Reports in Nephrology Volume 2019, Article ID 5149762, 6 pages https://doi.org/10.1155/2019/5149762 Case Report Two Cases of the MYH9 Disorder Fechtner Syndrome Diagnosed from Observation of Peripheral Blood Cells before End-Stage Renal Failure Shin Teshirogi,1 Jun Muratsu ,1 Hidenori Kasahara,1 Ken Terashima,1 Sho Miki,1 Tomohiro Minami,1 Yujiro Okute,1 Suguru Yoneda,1 Atsuyuki Morishima ,1 Shinji Kunishima,2 and Katsuhiko Sakaguchi 1 1Department of Nephrology and Hypertension, Sumitomo Hospital, 5-3-20 Nakanoshima, Kita-ku, Osaka 530-0005, Japan 2Department of Advanced Diagnosis, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan Correspondence should be addressed to Jun Muratsu; [email protected] Received 22 June 2019; Revised 21 August 2019; Accepted 4 October 2019; Published 26 November 2019 Academic Editor: Yoshihide Fujigaki Copyright © 2019 Shin Teshirogi et al. is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. As a MYH9 disorder, Fechtner syndrome is characterized by nephritis, giant platelets, granulocyte inclusion bodies (Döhle-like bodies), cataract, and sensorineural deafness. Observation of peripheral blood smear for the presence of thrombocytopenia, giant platelets, and granulocyte inclusion bodies (Döhle-like bodies) is highly important for the early diagnosis of MYH9 disorders. In our two cases, sequencing analysis of the MYH9 gene indicated mutations in exon 24. Both cases were diagnosed as the MYH9 disorders Fechtner syndrome before end-stage renal failure on the basis of the observation of peripheral blood smear. -
MYH9 Mutation, the Hidden Face of Diverse Disease
Urology & Nephrology Open Access Journal Case Report Open Access MYH9 mutation the hidden face of diverse disease spectrum - from renal perspective; renal perspective of MYH9 mutation Abstract Volume 5 Issue 4 - 2017 MYH9 (myosin heavy chain 9)-mutation is a frequent genetic disorder among African- 1 1 Americans and rare in Caucasians that can lead to dramatic deterioration of renal function Assel Rakhmetova, Pakesh Baishya, Pouneh 1 2 1 and as a consequence, end stage renal disease (ESRD). The clinical presentation of MYH9 Dokouhaki, Abdullah Alabbas, Kim Solez 1 mutations includes five syndromes: May-Hegglin anomaly, Sebastian, Fechtner, Epstein Department of laboratory medicine and pathology, University syndromes and isolated sensorineural deafness. The diagnosis is challenging to establish of Alberta hospital, Canada 2Department of pediatrics, division of nephrology, University of due to non-specific presentation that requires exclusion of a vast number of other entities. Alberta hospital, Canada Renal biopsy is not commonly performed but it may reveal non-specific findings such as mesangial expansion with hypercellularity, focal segmental glomerulosclerosis (FSGS) Correspondence: Pakesh Baishya, Department of laboratory and/or global glomerulosclerosis usually with no immune complex deposition. The medicine and pathology, University of Alberta hospital, immunostaining study for alpha-smooth muscle actin (SMA) can be valuable to perform Edmonton, Alberta, Canada, Tel 1 5875328105, in patients suspected to have MYH9 mutations in order to detect early FSGS. Additional Email studies for patients presenting with thrombocytopenia, decreasing glomerular filtration rate, proteinuria and haematuria are suggested. Here, we report a child with classic clinical picture Received: December 10, 2017 | Published: October 26, 2017 of MYH9 genetic disorder that presented with early focal segmental glomerulosclerosis with possible concurrent C1q nephropathy. -
Article Utility of Urine Eosinophils in the Diagnosis of Acute Interstitial
Article Utility of Urine Eosinophils in the Diagnosis of Acute Interstitial Nephritis Angela K. Muriithi,* Samih H. Nasr,† and Nelson Leung* Summary Background and objectives Urine eosinophils (UEs) have been shown to correlate with acute interstitial nephritis (AIN) but the four largest series that investigated the test characteristics did not use kidney biopsy as the gold standard. *Division of Nephrology and Hypertension, Design, setting, participants, & measurements This is a retrospective study of adult patients with biopsy-proven Department of diagnoses and UE tests performed from 1994 to 2011. UEs were tested using Hansel’s stain. Both 1% and 5% UE Internal Medicine, cutoffs were compared. Mayo Clinic, Rochester, Minnesota; and †Department of Results This study identified 566 patients with both a UE test and a native kidney biopsy performed within a week Laboratory Medicine of each other. Of these patients, 322 were men and the mean age was 59 years. There were 467 patients with and Pathology. Mayo pyuria, defined as at least one white cell per high-power field. There were 91 patients with AIN (80% was drug Clinic, Rochester, induced). A variety of kidney diseases had UEs. Using a 1% UE cutoff, the comparison of all patients with AIN to Minnesota those with all other diagnoses showed 30.8% sensitivity and 68.2% specificity, giving positive and negative ’ Correspondence: likelihood ratios of 0.97 and 1.01, respectively. Given this study s 16% prevalence of AIN, the positive and Dr. Angela K. Muriithi, negative predictive values were 15.6% and 83.7%, respectively. At the 5% UE cutoff, sensitivity declined, but Mayo Clinic, Division specificity improved. -
A Complicated Case of Von Hippel-Lindau Disease
Postgrad Med J 2001;77:471–480 471 Postgrad Med J: first published as 10.1136/pmj.77.909.478 on 1 July 2001. Downloaded from SELF ASSESSMENT QUESTIONS A complicated case of von Hippel-Lindau disease G Thomas, R Hillson Answers on p 481. A 17 year old female shop assistant presented with a three week history of generalised headache, associated with nausea, vomiting, and vertigo. She had no past medical history, and was taking no regular medication. Her mother was currently receiving radiotherapy for anaplastic carcinoma of the thyroid gland. On examination she had an ataxic gait, bilateral papilloedema, and horizontal nystagmus to right lateral gaze. Left sided dysdiadokinesis and hyper-reflexia were demonstrated. Power and sensation were preserved. Computed tom- ography of the brain revealed a cystic lesion within the left cerebellum. Subsequent mag- netic resonance imaging (MRI) revealed a sec- ond, non-cystic lesion within the region of the right vermis (fig 1). Both images were consist- ent with cerebellar haemangioblastomata. A posterior fossa craniotomy was performed, with successful excision of both tumours. She made an uneventful recovery, with complete resolution of all symptoms, and was subse- Figure 3 MIBG isotope quently discharged. uptake scan. During a follow up outpatient appointment Figure 1 MRI of the brain. six months later, she complained of frequent panic attacks, associated with sweating and http://pmj.bmj.com/ palpitation that had begun two months earlier. These episodes were precipitated by exercise or excitement. She gave no history of heat intoler- Department of ance, weight loss, or diarrhoea. Examination Diabetes and was entirely normal. -
Genetic Disorders of the Glomerular Filtration Barrier
CJASN ePress. Published on April 23, 2020 as doi: 10.2215/CJN.11440919 Genetic Disorders of the Glomerular Filtration Barrier Anna S. Li,1,2 Jack F. Ingham,1 and Rachel Lennon 1,3 Abstract The glomerular filtration barrier is a highly specialized capillary wall comprising fenestrated endothelial cells, podocytes, and an intervening basement membrane. In glomerular disease, this barrier loses functional integrity, allowing the passage of macromolecules and cells, and there are associated changes in both cell morphology and the extracellular matrix. Over the past three decades there has been a transformation in our understanding about glomerular disease, fueled by genetic discovery, and this is leading to exciting advances in our knowledge about 1Division of Cell- glomerular biology and pathophysiology. In current clinical practice, a genetic diagnosis already has important Matrix Biology and implications for management ranging from estimating the risk of disease recurrence post-transplant to the life- Regenerative changing advances in the treatment of atypical hemolytic uremic syndrome. Improving our understanding about Medicine, Wellcome Centre for Cell-Matrix the mechanistic basis of glomerular disease is required for more effective and personalized therapy options. In this Research, School of review we describe genotype and phenotype correlations for genetic disorders of the glomerular filtration barrier, Biological Sciences, with a particular emphasis on how these gene defects cluster by both their ontology and patterns of glomerular Faculty of Biology, pathology. Medicine and Health, CJASN ccc–ccc Manchester Academic 15: , 2020. doi: https://doi.org/10.2215/CJN.11440919 Health Science Centre, The University of Manchester, Introduction fenestrae that are 70–100 nm in diameter and covered Manchester, United . -
The First Case of MYH9 Related Disorder in Serbia Kongenitalna Trombocitopenija Sa Nefritisom – Prvi Bolesnik Sa MYH9 Poremeüajem U Srbiji
Vojnosanit Pregl 2014; 71(4): 395–398. VOJNOSANITETSKI PREGLED Strana 395 UDC: 575:61]:[616.155.2-056.7:616.61 CASE REPORTS DOI: 10.2298/VSP121127001K Congenital thrombocytopenia with nephritis – The first case of MYH9 related disorder in Serbia Kongenitalna trombocitopenija sa nefritisom – prvi bolesnik sa MYH9 poremeüajem u Srbiji Miloš Kuzmanoviü*†, Shinji Kunishima‡, Jovana Putnik†, Nataša Stajiü*†, Aleksandra Paripoviü†, Radovan Bogdanoviü*† *Faculty of Medicine, University of Belgrade, Belgrade, Serbia; †Institute of Mother and Child Health Care of Serbia „Dr Vukan ýupiü“, Belgrade, Serbia; ‡Department of Advanced Diagnosis, Clinical Research Center, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan Abstract Apstrakt Introduction. The group of autosomal dominant disor- Uvod. Grupu autozomno dominantnih poremeýaja – Ep- ders – Epstein syndrome, Sebastian syndrome, Fechthner steinov sindrom, Sebastianov sindrom, Fechthnerov sindrom syndrome and May-Hegglin anomaly – are characterised i May-Hegglinovu anomaliju – odlikuju trombocitopenija sa by thrombocytopenia with giant platelets, inclusion bod- džinovskim trombocitima, inkluzije u granulocitima, kao i ra- ies in granulocytes and variable levels of deafness, dis- zliÿita zastupljenost gluvoýe, poremeýaja vida i funkcije bub- turbances of vision and renal function impairment. A rega. Genetska osnova ovih sindroma su mutacije u genu za common genetic background of these disorders are mu- teški lanac nemišiýnog miozina IIA, a za ovu grupu sindroma tations in MYH9 gene, coding for the nonmuscle myosin predložen je naziv bolesti vezane za MYH9. Diferencijalna heavy chain IIA. Differential diagnosis is important for dijagnoza prema trombocitopenijama druge etiologije je zna- the adequate treatment strategy. The aim of this case re- ÿajna zbog pravilnog izbora terapijskih postupaka. Cilj rada port was to present a patient with MYH9 disorder in bio je prikaz bolesnika sa MYH9 poremeýajem u Srbiji. -
Medical Attention for Nephropathy)
PT‐ 2020 Measure Value Set_CDC (Medical Attention for Nephropathy) Numerator Value Set Name Code Definition Code System Urine Protein Tests 81000 CPT Urine Protein Tests 81001 CPT Urine Protein Tests 81002 CPT Urine Protein Tests 81003 CPT Urine Protein Tests 81005 CPT Urine Protein Tests 82042 CPT Urine Protein Tests 82043 CPT Urine Protein Tests 82044 CPT Urine Protein Tests 84156 CPT Urine Protein Tests 3060F Positive microalbuminuria test result documented and reviewed (DM) CPT‐CAT‐II Urine Protein Tests 3061F Negative microalbuminuria test result documented and reviewed (DM) CPT‐CAT‐II Urine Protein Tests 3062F Positive macroalbuminuria test result documented and reviewed (DM) CPT‐CAT‐II Urine Protein Tests 11218‐5 Microalbumin [Mass/volume] in Urine by Test strip LOINC Urine Protein Tests 12842‐1 Protein [Mass/volume] in 12 hour Urine LOINC Urine Protein Tests 13705‐9 Albumin/Creatinine [Mass Ratio] in 24 hour Urine LOINC Urine Protein Tests 13801‐6 Protein/Creatinine [Mass Ratio] in 24 hour Urine LOINC Urine Protein Tests 13986‐5 Albumin/Protein.total in 24 hour Urine by Electrophoresis LOINC Urine Protein Tests 13992‐3 Albumin/Protein.total in Urine by Electrophoresis LOINC Urine Protein Tests 14956‐7 Microalbumin [Mass/time] in 24 hour Urine LOINC Urine Protein Tests 14957‐5 Microalbumin [Mass/volume] in Urine LOINC Urine Protein Tests 14958‐3 Microalbumin/Creatinine [Mass Ratio] in 24 hour Urine LOINC Urine Protein Tests 14959‐1 Microalbumin/Creatinine [Mass Ratio] in Urine LOINC Urine Protein Tests 1753‐3 Albumin [Presence] -
Eosinophiluria in Relation to Pyelonephritis in Women
Journal of Advanced Laboratory Research in Biology E-ISSN: 0976-7614 Volume 6, Issue 4, 2015 PP 108-110 https://e-journal.sospublication.co.in Research Article Eosinophiluria in relation to Pyelonephritis in Women Pritam Singh Ajmani* Department of Pathology, R.D. Gardi Medical College, Surasa, Ujjain, Madhya Pradesh-456006, India. Abstract: In the present study of outpatient settings, pyelonephritis was diagnosed by the history and physical examination and supported by urinalysis results. After a clinco-pathological confirmation of pyelonephritis in 100 female patients in the age group between 18-55 years were selected. The urine samples were subjected for routine urine analysis and urine sediment was stained with Wright-Giemsa stain. A total of 13% of these patients had eosinophils in urine. Eosinophiluria is defined as the presence of more than 1% eosinophils in urinary sediment under the microscope. Eosinophiluria proved to be good predictors of pyelonephritis, however, it is not specific. Positive test for pyuria of moderate to severe were seen in all (100%) of the cases. Microscopic hematuria was seen in 18% cases. We have found that Wright-Giemsa stain results show consistent results and eosinophils were more easily recognized. Demographic data collected were age, weight, gravidity, and parity. The gestational age of diagnosis was recorded. Keywords: Urine, Wright-Giemsa Stain, Eosinophiluria. 1. Introduction 3. Microscopic Pyuria. 4. Gross Hematuria. Pyelonephritis is a common bacterial infection of 5. Microscopic Hematuria. the renal pelvis and kidney that usually results from 6. WBC casts Indicative of renal origin. ascent of a bacterial pathogen up the ureters from the 7. -
USMLE and COMLEX II
USMLE and COMLEX Review Nephrology Supplement Glomerulonephritis, Acute Tubular Necrosis and Acute Interstitial Nephritis Northwestern Medical Review www.northwesternmedicalreview.com Lansing, Michigan 2014-2015 1. What is Tamm-Horsfall glycoprotein (THP)? Matching (4 – 15): Match the following urinary casts with the descriptions, conditions, or questions _______________________________________ presented hereafter: _______________________________________ A. Bacterial casts _______________________________________ B. Crystal casts _______________________________________ C. Epithelial casts D. Fatty casts _______________________________________ E. Granular casts _______________________________________ F. Hyaline casts G. Pigment casts H. Red blood cell casts 2. What is a urinary cast? I. Waxy casts J. White blood cell casts _______________________________________ _______________________________________ 4. These types of casts are by far the most common _______________________________________ urinary casts. They are composed of solidified Tamm-Horsfall mucoprotein and secreted from _______________________________________ tubular cells under conditions of oliguria, _______________________________________ concentrated urine, and acidic urine. _______________________________________ _______________________________________ _______________________________________ 5. These types of casts are pathognomonic of acute tubular necrosis (ATN) and at times are 3. What are the major types of urinary casts? described as “muddy brown casts”. _______________________________________ -
Drug Induced Nephropathy Cases
Drug Induced Nephropathy Cases 1. H.H., 43 y.o., 80 kg male being treated for gram-negative septic shock • Admitted to hospital 6 days ago, and has spent the last 3 days intubated in the ICU because of hypotension, respiratory failure, and altered mental status. On admission, H.H. was started on ceftriaxone 2 g IV daily, gentamicin 140 mg IV q8h. • Admission labs: – BUN 13 mg/dL (5-20) – SCr 0.9 mg/dL (0.5-1.2) – Serial, blood, urine, and sputum cultures were positive for Acinetobacter baumanii sensitive to ceftriaxone and gentamicin. • Current medications – Ceftriaxone 2 g IV daily – Gentamicin 140 mg IV q8h. – Norepinephrine IV 18 mcg/min – Pancuronium 0.02 mg/kg IV q3h – Famotidine 20 mg IV q12h – Lorazepam IV 2 mg/hr • Today (hospital day 7) vital signs: – Temp 101.5 F (38.6 C) – BP 90/40 mmHg – Pulse 135 beats/min – Respirations 20 breaths/min • Labs: • BUN 67 mg/dL • SCr 5.4 mg/dL • WBC 16,700 cells/mm3 • Urinalysis: – Many WBC (0-5) – 3% RBC casts (0-1%) – Granular casts – Osmolality 250 mOsm/kg (400-600) • Serum gentamicin with last dose: – Peak 15 mg/dL (target 6-10) – Trough 9.1 mg/dL (target <2) a) Circle the renal parameters that are abnormal. b) What drug is most likely associated with the abnormal renal labs? 1 c) What information did you use to arrive at your assessment? 2. J.S., 50 y.o. female with cellulitus • In hospital blood and wound cultures were positive for methicillin-sensitive Staphylococcus aureus • Received 2 full days nafcillin 2 g IV q4h and then was discharged home on dicloxacillin 500 mg PO QID x 14 d • 10 days post discharge, J.S.